Biarylsulfonamide CCR9 inhibitors for inflammatory bowel disease.
Bioorg Med Chem Lett
; 25(17): 3661-4, 2015 Sep 01.
Article
em En
| MEDLINE
| ID: mdl-26117562
ABSTRACT
Inflammatory bowel disease, including Crohn's disease and ulcerative colitis, affects millions of people worldwide. CCR9 has been shown to be a key chemokine receptor mediating the local inflammatory responses in the GI tract. The CCR9 inhibitor Vercirnon advanced to phase 3 clinical trials, but carries several liabilities which we sought to improve.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Sulfonamidas
/
Doenças Inflamatórias Intestinais
/
Receptores CCR
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article